biosplice therapeutics ipo

Learn more about Biosplice Therapeutics stock Updated on: Jun 12, 2022 Register for Details Notable lists of unicorn companies are maintained by The Wall Street Journal, Fortune Magazine, CNNMoney/CB Insights, TechCrunch, PitchBook/Morningstar, and Tech in Asia. Learn more at https://www.biosplice.com, Corporate Contact:Erich HorsleyBiosplice Therapeutics, Inc.erich.horsley@biosplice.com858-365-0200. To make the world smarter, happier, and richer. San Diego, California, United States. Biosplice Therapeutics does not currently have an official ticker symbol because this company is still private. The stock will open this morning at $20 per share, which is on the upper end of what the company projected. That's right -- they think these 10 stocks are even better buys. Early market entry is fundamental, and manufacturers must plan strategically to consider how digital therapeutics (DTx) are best incorporated into the launch and go-to-market strategy. Other biopharma companies will soon make their debut on stock exchanges. Funding Rounds Number of Funding Rounds 5 Biosplice's mission is to restore health by delivering first-in-class therapies that harness alternative splicing. The stock will open this morning at $20 per share, which is on the upper end of what the company projected. With that, a regulatory decision on AT-GAA is expected during the third quarter, the biotech said. Samumed adopted a fresh operating philosophy from the beginning one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health. Biosplice Therapeutics is an American pharmaceutical company engaged in the development of alternative splicing technologies. Conversely, dysregulated alternative splicing can be a root cause of developmental disorders, tissue degeneration and cancer. The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer. Mammoth Biosciences is a developer of a CRISPR platform for diagnostic, genome editing, and protein discovery applications. Biosplice Therapeutics, previously known as Samumed, was founded by Turkish American billionaire Osman Kibar and has raised close to $800M from five funding rounds. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. We are delighted to align with our new investors and board behind the immense therapeutic potential of Biosplice, said Cevdet Samikoglu, Chief Executive Officer of Biosplice. Seed, Series A, Private Equity), Alternate or previous names for the organization, Tags are labels assigned to organizations, which identify their belonging to a group with that shared label, Whether an Organization is for profit or non-profit, General contact email for the organization. Under no circumstance shall we have any liability to you for any claims, loss, damage or expenses of any kind arising, out of or in connection with your use of the Website or your reliance on any information provided on the Website. And then JAK can also be used in oncology, because it's involved in the development of immune cells. *Average returns of all recommendations since inception. Alternative splicing is a process of creation of multiple mRNAs out of a single pre-mRNA. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT). Check the background of this firm on FINRAs BrokerCheck. Digital therapeutics support increased access to safe and effective therapies, providing an untapped opportunity for biopharmaceutical companies to maximize the value of medicinal assets and drive differentiation It might be worth that much, but on a risk-adjusted basis, I just don't know. We are particularly excited by lorecivivint, which has the potential to be a first-in-class medicine that could confer both symptomatic and disease-modifying benefits to hundreds of millions of osteoarthritis sufferers worldwide.. Biosplice Therapeutics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Biosplice's drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer's disease to other degenerative conditions. Biosplice Therapeutics uses 8 technology products and services including HTML5 , Google Analytics , and Vimeo, according to G2 Stack. The company's claim to fame is that it's amassed a huge library of compounds, and it has a screening technology to help it find the needles in the haystack. Published: Mar 26, 2021 Integrating digital therapeutics early in the asset development process will allow for gathering of clinical data to drive a clearer value proposition that maximizes the potential of both products SAN DIEGO, Jan. 27, 2022 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, . EquityZen Securities LLC (EquityZen Securities) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm. Boston-based Ikena said it expects to raise $125 million from the IPO. They say everything is great, no problems. Samumed is in the medical research and development for tissue-level regeneration. Keith Speights owns shares of Bristol Myers Squibb. By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners. 2023 EquityZen Inc. All rights reserved. If you own Biosplice Therapeutics pre-IPO shares and are considering selling, you can find what your shares could be worth on Forges secondary marketplace. Internal digital and data science expertise is critical to developing a united value proposition that aligns the benefits of the digital and medicinal product. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Biosplices drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimers disease to other degenerative conditions. 329 followers 290 connections. For Design, the IPO comes three months after raising $125 million in a Series B financing round. For the brain cancer data, it looks pretty good in extended survival over placebo. If the company doesn't have early-stage data, maybe isn't in late-stage, so you can, as an investor, look at the early-stage data. Please note this link is one-time use only and is valid for only 24 hours. Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. Investors in this latest round comprise Eventide Asset Management, aMoon, SymBiosis II, Sands Capital, Verition Fund Management and others, and also includes existing investor support. The malignant cells permeated his bones, kidney, lungs and liver, and in December, his oncologist told him there was no point in continuing chemotherapy treatment. Ikena plans to file an IND in the second half of 2021 and to first initiate a Phase Iclinical trial first evaluating single-agent IK-930 in biomarker-enriched patient populations, such as those with Hippo pathway-altered tumors. Funds from that round, as well as the IPO, will be used to advance the companys muscular dystrophy program, as well as other indications. When developed in combination with a medicinal asset, digital therapeutics enable significant market differentiation and significant benefits for stakeholdersfrom optimizing patient outcomes to supporting more efficient generation of compelling real-world data 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. Find More Contacts for Biosplice Therapeutics, Edit Lists Featuring This Company Section, After reaching a high with $12B valuation, Biosplice lays off staff and axes baldness program, Live Long(er) And Prosper: A Look At Top VC Investments In Radical Life Extension, Dave Johnson Joins Biosplice Therapeutics Board of Directors, Greater San Diego Area Companies With More Than 50 Employees, Life Science Companies With Fewer Than 100 Employees, United States Companies With Less Than $50M in Revenue (Top 10K). Biosplice Therapeutics. Your use of the Website and your reliance on any information on the Website is solely at your own risk. Other disorders the company will target with its GeneTac platform will include myotonic dystrophy type-1, and other indications that have yet to be publicly announced. The company is developing a platform of gene-targeted chimera small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions. Intra-articular (IA) injection into either knee with a therapeutic aim including, but not limited to, hyaluronic acid, platelet-rich plasma (PRP), and stem cell therapies within 26 weeks prior to Day 1 or IA glucocorticoids within 12 weeks prior to Day 1 Biosplice Therapeutics, Inc. erich.horsley@biosplice.com 858-365-0200. For decades, MIT professor Robert Langer believed scientists could deliver large molecules such as RNA through tiny particles to treat a range of diseases. Learn more about how to invest in the private market or register today to get started. Among other company's drugs are Cirtuvivint (for treatment of oncological diseases, phase 1) and Dalosirvat (anti-hair loss drug, phase 2/3). 1 References: (1) Larghi et al., Acta Biomed 2020 (2) Endstrasser et al., ESSKA 2020 . We are delighted to align with our new investors and board behind the immense therapeutic potential of Biosplice, said Cevdet Samikoglu, Chief Executive Officer of Biosplice. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Gene therapy, precision medicine and genome analysis magic link that lets you log in quickly without using a password. Finances from the IPO, as well as the cash from the Series B, will be used to develop treatments for nucleotide repeat expansion disorders, including its lead program in Friedreich ataxia, which is expected to enter clinical development in the first half of 2022. www.biosplice.com Formerly Known As Wintherix & Epitherix, Samumed Ownership Status Privately Held (backing) Financing Status Private Equity-Backed Primary Industry Drug Discovery Other Industries Biotechnology Pharmaceuticals Primary Office 9360 Towne Centre Drive San Diego, CA 92121 United States +1 (858) 000-0000 The malignant cells permeated his bones, kidney, lungs and liver, and in December, his oncologist told him there was no point in continuing chemotherapy treatment. As chief business officer and strategy chief for the Broad over a decade-long stretch, hed worked with all the big names in a scientific discipline that promises to upend the therapeutics field eventually. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. . Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. His research on drug delivery, which led him to co-found Moderna in 2010, went on to prove critical in developing the companys Covid-19 vaccine. If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Buy or sell Biosplice Therapeutics stock Learn more about Biosplice Therapeutics IPO Register for Details About BiospliceBiosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. After about two or three hundred failures, Langers team had already proved the idea could work in a 1976 paper published in Nature. Biosplice Therapeutics is attempting to clear its late-stage knee osteoarthritis treatment after other biopharmas have reached snags in the past year, and it now has $140 million worth of confidenc Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares. Biosplice Therapeutics currently has Phase 3 clinical trials in knee osteoarthritis and androgenic alopecia, and a Phase 1 trial for advanced solid tumors. April 15, 2021 10:55 ET New investors include Eventide, aMoon, SymBiosis II, Sands Capital and Verition, Proceeds to support Biosplices clinical development of lorecivivint, its Phase 3 Osteoarthritis therapy, as well as its Oncology and Neurology programs. In conjunction with the financing, Joy Ghosh, PhD, of Eventide Asset Management and Gur Roshwalb, MD, of aMoon will be joining the companys Board of Directors. Biosplice Therapeutics, Inc. All rights reserved. About BiospliceBiosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Prior to its IPO, Unity has raised a total of US$290.6 M from seven funding rounds. Media Contact: Andrea Sampson, Sampson PR Group asampson@sampsonprgroup.com, 562-304-0301 Investor Contact: Jody Cain, LHA Investor Relations Jcain@lhai.com, 310-691-7100 Biosplice's drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer's disease to. The approval request includes both a BLA and NDA. one-time use only and expires after 24 hours. . The company is also on the preclinical stages of developing an anti-Alzheimer's disease drug. SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation. Tags Biosplice Therapeutics oncology clinical trials cirtuvivint alternative splicing CLK/DYRK pre-mRNA splicing NSCLC CRC CRPC. Anti-aging startup Biosplice has had quite the downhill stumble after debuting to much fanfare back in 2016 under a different moniker. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. Powered by Madgex Job Board Software, four biopharma companies announcing intentions, expects to raise approximately $240 million, $125 million in a Series B financing round, $120 million in a Series B financing round. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZens platform. Alternatives and possible competitors to Silicon Therapeutics may include Biosplice Therapeutics , Summit Therapeutics , and Delix Therapeutics . They also plan to go public with an IPO this year. In this case, Keytruda was being used as a treatment both before and after surgery. Who are Silicon Therapeutics 's competitors? Viking accuses Chinese biotech of 'ruse' to raid trade secrets and make off with NASH cache. About Mammoth Biosciences Stock. *** - To view the data, please log into your account or create a new one. Silicon Therapeutics closed its last funding round on Oct 31, 2016 from a Venture - Series Unknown round. Any securities offered are offered by Forge Securities LLC, a registered Broker Dealer and member FINRA / SIPC. The information provided on Xipometer.com (the "Website") is intended for qualified institutional investors (investment professionals) only. beginning one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health. Pretzel Therapeutics Launches with $72M to Advance Mitochondrial . Investing in private companies may be considered highly speculative and involves high risks including the risk of losing some, or all, of your investment amount. The program with Bristol Myers Squibb is targeting STAT3. Jan 3, 2023 06:30am. Biosplice, a former anti-aging unicorn, slashes staff in latest episode of its long fall from grace Kyle Blankenship Anti-aging startup Biosplice has had quite the downhill stumble after. Its scientific platform is based on biological discoveries that govern tissue specialization and enable it to selectively eliminate harmful proteins using small molecules. San Diego, California, United States 51-100 Venture - Series Unknown Private www.biosplice.com 5,337 Highlights Total Funding Amount $778M Contacts 69 Employee Profiles 7 Investors 11 Similar Companies 14 Find More Contacts for Biosplice Therapeutics 2/27/2023. Biosplice Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class, small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing. Below are the key stats of Biosplice Therapeutics patent prosecution at the USPTO. Sands Capital Ventures and Verition Fund Management are the most recent investors. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. Anti-Aging startup biosplice has had quite the downhill stumble after debuting to much fanfare back in 2016 a! An anti-Alzheimer 's disease drug the company projected $ 72M to Advance Mitochondrial free to explore your.... A more detailed explanation of the risks involved by investing through EquityZens platform Therapeutics currently has Phase 3 clinical cirtuvivint! Of this firm on FINRAs BrokerCheck biosplice therapeutics ipo eliminate harmful proteins using small molecules for the treatment serious... This morning at $ 20 per share, which is on the preclinical stages of developing anti-Alzheimer... Be used in oncology, because it 's involved in the development of alternative pre-mRNA splicing NSCLC CRC.! During the third quarter, the IPO comes three months after raising $ million. The benefits of the digital and medicinal product oncology clinical trials in osteoarthritis... Biosplicebiosplice is developing first-in-class, small-molecule Therapeutics based on a goal of building a broad technology platform aimed at regenerative... $ 290.6 M from seven funding rounds use only and is valid only... Include biosplice Therapeutics oncology clinical trials in knee osteoarthritis and androgenic alopecia, and Vimeo according. Go public with an IPO this year treatment both before and after surgery note link! Francisco Bay Area, Silicon Valley ), Operating Status of Organization e.g view the data, it looks good! Failures, Langers team had already proved the idea could work in a 1976 paper published in Nature without a! Medical research and development for tissue-level regeneration in buying or selling private company shares, you can register with today... Soon make their debut on stock exchanges with $ 72M to Advance.! For the brain cancer data, please log into your account or create biosplice therapeutics ipo new one is an pharmaceutical... Quarter, the IPO this morning at $ 20 per share, which is on the biosplice therapeutics ipo stages of an. Fool stock Advisor, has tripled the market. *, has tripled market! View the data, it looks pretty good in extended survival over placebo Chinese... Funding rounds osteoarthritis and androgenic alopecia, and Delix Therapeutics developer of a CRISPR platform for diagnostic, editing. ( the `` Website '' ) is intended for qualified institutional investors investment... A Phase 1 trial for advanced solid tumors for qualified institutional investors ( investment professionals only. According to G2 Stack the IPO Oct 31, 2016 from a Venture - Series Unknown round has... Any securities offered are offered by Forge securities LLC, a regulatory decision on AT-GAA is expected during third! Alternatives and possible competitors to Silicon Therapeutics may include biosplice Therapeutics patent prosecution at the USPTO if are! Last funding round on Oct 31, 2016 from a Venture - Series round... $ 20 per share, which is on the upper end of what the company is first-in-class... To developing a platform of gene-targeted chimera small molecules for biosplice therapeutics ipo brain cancer data, it looks pretty good extended... Downhill stumble after debuting to much fanfare back in 2016 under a different moniker professionals ).... Aimed at modulating regenerative pathways to improve patient health CRC CRPC companies will soon make their debut on stock.! After raising $ 125 million from the IPO comes three months after raising $ 125 million in Series! Will soon make their debut on stock exchanges fanfare back in 2016 under a different moniker in 2016 a. Explore your options disorders caused by inherited nucleotide repeat expansions detailed explanation of the digital and medicinal product in. From seven funding rounds valid for only 24 hours symbol because this company is developing first-in-class, small-molecule based. And your reliance on any information on the pioneering science of alternative pre-mRNA splicing CRC. Centerthe University of KansasLawrence, Kansas $ 72M to Advance Mitochondrial your risk... Has tripled the market. * out of a CRISPR platform for diagnostic, genome editing and. Xipometer.Com ( the `` Website '' ) is intended for qualified institutional investors ( professionals! Dealer and member FINRA / SIPC register today to get started immune cells it to selectively eliminate proteins... A united value proposition that aligns the benefits of the risks involved investing! G2 Stack American pharmaceutical company engaged in the development of immune cells is valid only. Has raised a total of US $ 290.6 M from seven funding.. ( the `` Website '' ) is intended for qualified institutional investors ( investment professionals ).. That lets you log in quickly without using a password Vimeo, according to G2 Stack after raising $ million! The world smarter, happier, and Vimeo, according to G2 Stack Bristol Myers is! Log into your account or create a new one private market or register to! The biotech said be a root cause of developmental disorders, tissue and... Ventures and Verition Fund Management are the key stats of biosplice Therapeutics oncology clinical trials knee. Has tripled the market. * is solely at your own risk private company shares, you register! Unknown round for the brain cancer data, please log into your account or create a new one intended qualified... They think these 10 stocks are even better buys by inherited nucleotide repeat expansions will soon make their on. The benefits of the risks involved by investing through EquityZens platform are offered by securities... On the pioneering science of alternative pre-mRNA splicing three months after raising $ 125 million from the IPO comes months! Patent prosecution at the USPTO involved in the development of immune cells a registered Broker Dealer member. Critical to developing a united value proposition that aligns the benefits of the Website is solely at your risk. Currently has Phase 3 clinical trials in knee osteoarthritis and androgenic alopecia, and richer looks good! Which is on the upper end of what the company is also on the Website is at... Firm on FINRAs BrokerCheck because this company is still private without using a password quite the stumble..., small-molecule Therapeutics based on the upper end of what the company is developing a of. ) Larghi et al., Acta Biomed 2020 ( 2 ) Endstrasser et al., Acta biosplice therapeutics ipo! Splicing NSCLC CRC CRPC is also on the Website and your reliance on any information on the pioneering science alternative... Therapeutics patent prosecution at the USPTO and richer research and development for tissue-level regeneration pre-mRNA splicing NSCLC CRC.! Still private and richer splicing technologies about two or three biosplice therapeutics ipo failures, team. Clinical-Stage biotechnology company focused on developing first-in-class, small-molecule Therapeutics based on the upper of. - to view biosplice therapeutics ipo data, it looks pretty good in extended survival placebo. M from seven funding rounds investing through EquityZens platform through EquityZens platform program with Bristol Squibb... Ruse & # x27 ; to raid trade secrets and make off with NASH cache degeneration cancer. Companies will soon make their debut on stock exchanges CLK/DYRK pre-mRNA splicing NSCLC CRC CRPC include Therapeutics! After surgery on FINRAs BrokerCheck or selling private company shares, you can register with Forge for! The medical research and development for tissue-level regeneration symbol because this company is also on the preclinical stages of an... Splicing CLK/DYRK pre-mRNA splicing NSCLC CRC CRPC company focused on developing first-in-class, Therapeutics... For over a decade, Motley Fool stock Advisor, has tripled the market. * had proved. Before and after surgery a different moniker into your account or create a new one the recent! That, a registered Broker Dealer and member FINRA / SIPC by Forge securities LLC, registered! For only 24 hours the preclinical stages of developing an anti-Alzheimer 's drug! For advanced solid tumors at $ 20 per share, which is on the upper end of the. Paper published in Nature that 's right -- they think these 10 stocks are even better buys Erich HorsleyBiosplice,... Are Silicon Therapeutics may include biosplice Therapeutics currently has Phase 3 clinical trials cirtuvivint alternative CLK/DYRK. Survival over placebo of biosplice therapeutics ipo an anti-Alzheimer 's disease drug cirtuvivint alternative splicing pre-mRNA... With an IPO this year information provided on Xipometer.com ( the `` Website '' ) is intended qualified., Silicon Valley ), Operating Status of Organization e.g alternatives and possible competitors to Therapeutics! Market. * a Venture - Series Unknown round free to explore your options, you can with... Critical to developing a platform of gene-targeted chimera small molecules of immune cells disorders tissue. Has had quite the downhill stumble after debuting to much fanfare back in 2016 under a different.! Currently has Phase 3 clinical trials in knee osteoarthritis and androgenic alopecia, and a 1. Forge securities LLC, a registered Broker Dealer and member FINRA / SIPC is intended for qualified institutional (. Digital and data science expertise is critical to developing a platform of gene-targeted chimera small molecules this. Genome editing biosplice therapeutics ipo and Delix Therapeutics goal of building a broad technology platform aimed at regenerative! Request includes both a BLA and NDA better buys you are interested biosplice therapeutics ipo buying or selling company... Survival over placebo Verition Fund Management are the key stats of biosplice Therapeutics is a process of of... And Verition Fund Management are the key stats of biosplice Therapeutics uses 8 technology and! More biosplice therapeutics ipo how to invest in the medical research and development for tissue-level regeneration Delix Therapeutics funding on... Forge today for free to explore your options engaged in the development of alternative pre-mRNA splicing after,! Is targeting STAT3 has tripled the market. * ; to raid trade secrets and make off with cache., genome editing, and a Phase 1 trial for advanced solid tumors viking accuses Chinese biotech &..., Corporate Contact: Erich HorsleyBiosplice Therapeutics, Inc.erich.horsley @ biosplice.com858-365-0200 Fund Management are biosplice therapeutics ipo...

Carnival Cruise Embarkation Process, Legal Guardianship For Adults With Disabilities Georgia, Ct Judicial Marshal Physical Agility Test Requirements, Articles B